Report Detail

Request for Sample of this report

Pharma & Healthcare Global Central Nervous System Disease Drugs Market 2026 by Company, Regions, Type and Application, Forecast to 2032

  • RnM4745792
    • |
  • 28 September, 2026
    • |
  • Global
    • |
  • 126 Pages
    • |
  • GIR
    • |
  • Pharma & Healthcare

According to our (Global Info Research) latest study, the global Central Nervous System Disease Drugs market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report is a detailed and comprehensive analysis for global Central Nervous System Disease Drugs market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Central Nervous System Disease Drugs market size and forecasts, in consumption value ($ Million), 2021-2032
Global Central Nervous System Disease Drugs market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Central Nervous System Disease Drugs market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global Central Nervous System Disease Drugs market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Central Nervous System Disease Drugs
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Central Nervous System Disease Drugs market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Pfizer, Biogen, Otsuka, Novartis, Teva Pharmaceutical, Johnson & Johnson, AstraZeneca, Merck, GSK, Eli Lilly and Company, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Central Nervous System Disease Drugs market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Antidepressants
Antipsychotics
Anti-Dementia Drugs
Anti-Parkinson's Drugs
Antiepileptic Drugs
Others
Market segment by Application
Hospital and Clinic
Pharmacy
Market segment by players, this report covers
Pfizer
Biogen
Otsuka
Novartis
Teva Pharmaceutical
Johnson & Johnson
AstraZeneca
Merck
GSK
Eli Lilly and Company
Lundbeck
Takeda
Bristol Myers Squibb
Jiangsu Nhwa Pharmaceutical
Luye Pharma
Zhejiang Huahai Pharmaceutical
Chengdu Easton Biopharmaceuticals
Hansoh Pharmaceutical
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Central Nervous System Disease Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Central Nervous System Disease Drugs, with revenue, gross margin, and global market share of Central Nervous System Disease Drugs from 2021 to 2026.
Chapter 3, the Central Nervous System Disease Drugs competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Central Nervous System Disease Drugs market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Central Nervous System Disease Drugs.
Chapter 13, to describe Central Nervous System Disease Drugs research findings and conclusion.


1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Central Nervous System Disease Drugs by Type
    • 1.3.1 Overview: Global Central Nervous System Disease Drugs Market Size by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Global Central Nervous System Disease Drugs Consumption Value Market Share by Type in 2025
    • 1.3.3 Antidepressants
    • 1.3.4 Antipsychotics
    • 1.3.5 Anti-Dementia Drugs
    • 1.3.6 Anti-Parkinson's Drugs
    • 1.3.7 Antiepileptic Drugs
    • 1.3.8 Others
  • 1.4 Global Central Nervous System Disease Drugs Market by Application
    • 1.4.1 Overview: Global Central Nervous System Disease Drugs Market Size by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Hospital and Clinic
    • 1.4.3 Pharmacy
  • 1.5 Global Central Nervous System Disease Drugs Market Size & Forecast
  • 1.6 Global Central Nervous System Disease Drugs Market Size and Forecast by Region
    • 1.6.1 Global Central Nervous System Disease Drugs Market Size by Region: 2021 VS 2025 VS 2032
    • 1.6.2 Global Central Nervous System Disease Drugs Market Size by Region, (2021-2032)
    • 1.6.3 North America Central Nervous System Disease Drugs Market Size and Prospect (2021-2032)
    • 1.6.4 Europe Central Nervous System Disease Drugs Market Size and Prospect (2021-2032)
    • 1.6.5 Asia-Pacific Central Nervous System Disease Drugs Market Size and Prospect (2021-2032)
    • 1.6.6 South America Central Nervous System Disease Drugs Market Size and Prospect (2021-2032)
    • 1.6.7 Middle East & Africa Central Nervous System Disease Drugs Market Size and Prospect (2021-2032)

2 Company Profiles

  • 2.1 Pfizer
    • 2.1.1 Pfizer Details
    • 2.1.2 Pfizer Major Business
    • 2.1.3 Pfizer Central Nervous System Disease Drugs Product and Solutions
    • 2.1.4 Pfizer Central Nervous System Disease Drugs Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Pfizer Recent Developments and Future Plans
  • 2.2 Biogen
    • 2.2.1 Biogen Details
    • 2.2.2 Biogen Major Business
    • 2.2.3 Biogen Central Nervous System Disease Drugs Product and Solutions
    • 2.2.4 Biogen Central Nervous System Disease Drugs Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Biogen Recent Developments and Future Plans
  • 2.3 Otsuka
    • 2.3.1 Otsuka Details
    • 2.3.2 Otsuka Major Business
    • 2.3.3 Otsuka Central Nervous System Disease Drugs Product and Solutions
    • 2.3.4 Otsuka Central Nervous System Disease Drugs Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Otsuka Recent Developments and Future Plans
  • 2.4 Novartis
    • 2.4.1 Novartis Details
    • 2.4.2 Novartis Major Business
    • 2.4.3 Novartis Central Nervous System Disease Drugs Product and Solutions
    • 2.4.4 Novartis Central Nervous System Disease Drugs Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Novartis Recent Developments and Future Plans
  • 2.5 Teva Pharmaceutical
    • 2.5.1 Teva Pharmaceutical Details
    • 2.5.2 Teva Pharmaceutical Major Business
    • 2.5.3 Teva Pharmaceutical Central Nervous System Disease Drugs Product and Solutions
    • 2.5.4 Teva Pharmaceutical Central Nervous System Disease Drugs Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Teva Pharmaceutical Recent Developments and Future Plans
  • 2.6 Johnson & Johnson
    • 2.6.1 Johnson & Johnson Details
    • 2.6.2 Johnson & Johnson Major Business
    • 2.6.3 Johnson & Johnson Central Nervous System Disease Drugs Product and Solutions
    • 2.6.4 Johnson & Johnson Central Nervous System Disease Drugs Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Johnson & Johnson Recent Developments and Future Plans
  • 2.7 AstraZeneca
    • 2.7.1 AstraZeneca Details
    • 2.7.2 AstraZeneca Major Business
    • 2.7.3 AstraZeneca Central Nervous System Disease Drugs Product and Solutions
    • 2.7.4 AstraZeneca Central Nervous System Disease Drugs Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 AstraZeneca Recent Developments and Future Plans
  • 2.8 Merck
    • 2.8.1 Merck Details
    • 2.8.2 Merck Major Business
    • 2.8.3 Merck Central Nervous System Disease Drugs Product and Solutions
    • 2.8.4 Merck Central Nervous System Disease Drugs Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Merck Recent Developments and Future Plans
  • 2.9 GSK
    • 2.9.1 GSK Details
    • 2.9.2 GSK Major Business
    • 2.9.3 GSK Central Nervous System Disease Drugs Product and Solutions
    • 2.9.4 GSK Central Nervous System Disease Drugs Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 GSK Recent Developments and Future Plans
  • 2.10 Eli Lilly and Company
    • 2.10.1 Eli Lilly and Company Details
    • 2.10.2 Eli Lilly and Company Major Business
    • 2.10.3 Eli Lilly and Company Central Nervous System Disease Drugs Product and Solutions
    • 2.10.4 Eli Lilly and Company Central Nervous System Disease Drugs Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 Eli Lilly and Company Recent Developments and Future Plans
  • 2.11 Lundbeck
    • 2.11.1 Lundbeck Details
    • 2.11.2 Lundbeck Major Business
    • 2.11.3 Lundbeck Central Nervous System Disease Drugs Product and Solutions
    • 2.11.4 Lundbeck Central Nervous System Disease Drugs Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 Lundbeck Recent Developments and Future Plans
  • 2.12 Takeda
    • 2.12.1 Takeda Details
    • 2.12.2 Takeda Major Business
    • 2.12.3 Takeda Central Nervous System Disease Drugs Product and Solutions
    • 2.12.4 Takeda Central Nervous System Disease Drugs Revenue, Gross Margin and Market Share (2021-2026)
    • 2.12.5 Takeda Recent Developments and Future Plans
  • 2.13 Bristol Myers Squibb
    • 2.13.1 Bristol Myers Squibb Details
    • 2.13.2 Bristol Myers Squibb Major Business
    • 2.13.3 Bristol Myers Squibb Central Nervous System Disease Drugs Product and Solutions
    • 2.13.4 Bristol Myers Squibb Central Nervous System Disease Drugs Revenue, Gross Margin and Market Share (2021-2026)
    • 2.13.5 Bristol Myers Squibb Recent Developments and Future Plans
  • 2.14 Jiangsu Nhwa Pharmaceutical
    • 2.14.1 Jiangsu Nhwa Pharmaceutical Details
    • 2.14.2 Jiangsu Nhwa Pharmaceutical Major Business
    • 2.14.3 Jiangsu Nhwa Pharmaceutical Central Nervous System Disease Drugs Product and Solutions
    • 2.14.4 Jiangsu Nhwa Pharmaceutical Central Nervous System Disease Drugs Revenue, Gross Margin and Market Share (2021-2026)
    • 2.14.5 Jiangsu Nhwa Pharmaceutical Recent Developments and Future Plans
  • 2.15 Luye Pharma
    • 2.15.1 Luye Pharma Details
    • 2.15.2 Luye Pharma Major Business
    • 2.15.3 Luye Pharma Central Nervous System Disease Drugs Product and Solutions
    • 2.15.4 Luye Pharma Central Nervous System Disease Drugs Revenue, Gross Margin and Market Share (2021-2026)
    • 2.15.5 Luye Pharma Recent Developments and Future Plans
  • 2.16 Zhejiang Huahai Pharmaceutical
    • 2.16.1 Zhejiang Huahai Pharmaceutical Details
    • 2.16.2 Zhejiang Huahai Pharmaceutical Major Business
    • 2.16.3 Zhejiang Huahai Pharmaceutical Central Nervous System Disease Drugs Product and Solutions
    • 2.16.4 Zhejiang Huahai Pharmaceutical Central Nervous System Disease Drugs Revenue, Gross Margin and Market Share (2021-2026)
    • 2.16.5 Zhejiang Huahai Pharmaceutical Recent Developments and Future Plans
  • 2.17 Chengdu Easton Biopharmaceuticals
    • 2.17.1 Chengdu Easton Biopharmaceuticals Details
    • 2.17.2 Chengdu Easton Biopharmaceuticals Major Business
    • 2.17.3 Chengdu Easton Biopharmaceuticals Central Nervous System Disease Drugs Product and Solutions
    • 2.17.4 Chengdu Easton Biopharmaceuticals Central Nervous System Disease Drugs Revenue, Gross Margin and Market Share (2021-2026)
    • 2.17.5 Chengdu Easton Biopharmaceuticals Recent Developments and Future Plans
  • 2.18 Hansoh Pharmaceutical
    • 2.18.1 Hansoh Pharmaceutical Details
    • 2.18.2 Hansoh Pharmaceutical Major Business
    • 2.18.3 Hansoh Pharmaceutical Central Nervous System Disease Drugs Product and Solutions
    • 2.18.4 Hansoh Pharmaceutical Central Nervous System Disease Drugs Revenue, Gross Margin and Market Share (2021-2026)
    • 2.18.5 Hansoh Pharmaceutical Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Central Nervous System Disease Drugs Revenue and Share by Players (2021-2026)
  • 3.2 Market Share Analysis (2025)
    • 3.2.1 Market Share of Central Nervous System Disease Drugs by Company Revenue
    • 3.2.2 Top 3 Central Nervous System Disease Drugs Players Market Share in 2025
    • 3.2.3 Top 6 Central Nervous System Disease Drugs Players Market Share in 2025
  • 3.3 Central Nervous System Disease Drugs Market: Overall Company Footprint Analysis
    • 3.3.1 Central Nervous System Disease Drugs Market: Region Footprint
    • 3.3.2 Central Nervous System Disease Drugs Market: Company Product Type Footprint
    • 3.3.3 Central Nervous System Disease Drugs Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Central Nervous System Disease Drugs Consumption Value and Market Share by Type (2021-2026)
  • 4.2 Global Central Nervous System Disease Drugs Market Forecast by Type (2027-2032)

5 Market Size Segment by Application

  • 5.1 Global Central Nervous System Disease Drugs Consumption Value Market Share by Application (2021-2026)
  • 5.2 Global Central Nervous System Disease Drugs Market Forecast by Application (2027-2032)

6 North America

  • 6.1 North America Central Nervous System Disease Drugs Consumption Value by Type (2021-2032)
  • 6.2 North America Central Nervous System Disease Drugs Market Size by Application (2021-2032)
  • 6.3 North America Central Nervous System Disease Drugs Market Size by Country
    • 6.3.1 North America Central Nervous System Disease Drugs Consumption Value by Country (2021-2032)
    • 6.3.2 United States Central Nervous System Disease Drugs Market Size and Forecast (2021-2032)
    • 6.3.3 Canada Central Nervous System Disease Drugs Market Size and Forecast (2021-2032)
    • 6.3.4 Mexico Central Nervous System Disease Drugs Market Size and Forecast (2021-2032)

7 Europe

  • 7.1 Europe Central Nervous System Disease Drugs Consumption Value by Type (2021-2032)
  • 7.2 Europe Central Nervous System Disease Drugs Consumption Value by Application (2021-2032)
  • 7.3 Europe Central Nervous System Disease Drugs Market Size by Country
    • 7.3.1 Europe Central Nervous System Disease Drugs Consumption Value by Country (2021-2032)
    • 7.3.2 Germany Central Nervous System Disease Drugs Market Size and Forecast (2021-2032)
    • 7.3.3 France Central Nervous System Disease Drugs Market Size and Forecast (2021-2032)
    • 7.3.4 United Kingdom Central Nervous System Disease Drugs Market Size and Forecast (2021-2032)
    • 7.3.5 Russia Central Nervous System Disease Drugs Market Size and Forecast (2021-2032)
    • 7.3.6 Italy Central Nervous System Disease Drugs Market Size and Forecast (2021-2032)

8 Asia-Pacific

  • 8.1 Asia-Pacific Central Nervous System Disease Drugs Consumption Value by Type (2021-2032)
  • 8.2 Asia-Pacific Central Nervous System Disease Drugs Consumption Value by Application (2021-2032)
  • 8.3 Asia-Pacific Central Nervous System Disease Drugs Market Size by Region
    • 8.3.1 Asia-Pacific Central Nervous System Disease Drugs Consumption Value by Region (2021-2032)
    • 8.3.2 China Central Nervous System Disease Drugs Market Size and Forecast (2021-2032)
    • 8.3.3 Japan Central Nervous System Disease Drugs Market Size and Forecast (2021-2032)
    • 8.3.4 South Korea Central Nervous System Disease Drugs Market Size and Forecast (2021-2032)
    • 8.3.5 India Central Nervous System Disease Drugs Market Size and Forecast (2021-2032)
    • 8.3.6 Southeast Asia Central Nervous System Disease Drugs Market Size and Forecast (2021-2032)
    • 8.3.7 Australia Central Nervous System Disease Drugs Market Size and Forecast (2021-2032)

9 South America

  • 9.1 South America Central Nervous System Disease Drugs Consumption Value by Type (2021-2032)
  • 9.2 South America Central Nervous System Disease Drugs Consumption Value by Application (2021-2032)
  • 9.3 South America Central Nervous System Disease Drugs Market Size by Country
    • 9.3.1 South America Central Nervous System Disease Drugs Consumption Value by Country (2021-2032)
    • 9.3.2 Brazil Central Nervous System Disease Drugs Market Size and Forecast (2021-2032)
    • 9.3.3 Argentina Central Nervous System Disease Drugs Market Size and Forecast (2021-2032)

10 Middle East & Africa

  • 10.1 Middle East & Africa Central Nervous System Disease Drugs Consumption Value by Type (2021-2032)
  • 10.2 Middle East & Africa Central Nervous System Disease Drugs Consumption Value by Application (2021-2032)
  • 10.3 Middle East & Africa Central Nervous System Disease Drugs Market Size by Country
    • 10.3.1 Middle East & Africa Central Nervous System Disease Drugs Consumption Value by Country (2021-2032)
    • 10.3.2 Turkey Central Nervous System Disease Drugs Market Size and Forecast (2021-2032)
    • 10.3.3 Saudi Arabia Central Nervous System Disease Drugs Market Size and Forecast (2021-2032)
    • 10.3.4 UAE Central Nervous System Disease Drugs Market Size and Forecast (2021-2032)

11 Market Dynamics

  • 11.1 Central Nervous System Disease Drugs Market Drivers
  • 11.2 Central Nervous System Disease Drugs Market Restraints
  • 11.3 Central Nervous System Disease Drugs Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 Central Nervous System Disease Drugs Industry Chain
  • 12.2 Central Nervous System Disease Drugs Upstream Analysis
  • 12.3 Central Nervous System Disease Drugs Midstream Analysis
  • 12.4 Central Nervous System Disease Drugs Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    Summary:
    Get latest Market Research Reports on Central Nervous System Disease Drugs. Industry analysis & Market Report on Central Nervous System Disease Drugs is a syndicated market report, published as Global Central Nervous System Disease Drugs Market 2026 by Company, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Central Nervous System Disease Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    		$3,480.00
    		$5,220.00
    		$6,960.00
    		2,690.04
    		4,035.06
    		5,380.08
    		3,239.88
    		4,859.82
    		6,479.76
    		531,361.20
    		797,041.80
    		1,062,722.40
    		293,712.00
    		440,568.00
    		587,424.00
    Credit card Logo
    Sample Question Discount Download PDF

    Related Reports

    Reason to Buy

    • Trusted By Leaders

      Top executives from leading companies purchase research reports from us. 

    • Shop With Confidence

      We assist you with all the pre-sales enquiries related to any report so that you can buy with confidence.

    • Customer Centric

      Need assistance related to your research requirements? We are just a phone call or an email away.

    • Personalized Solutions

      Our experienced research specialists are here to help you locate the right reports for your need.

    • Secure Checkout

      Shop without being worried about safety & security of your transactions.
      •

    Request for Sample of this report

    Reports and Markets

    mcafree

    Contact Us

    +1-352-353-0818 (US)

    info@reportsandmarkets.com

    Support

    EMAIL US

    Newsletter

    KEEP UP TO DATE ON ALL THE LATEST REPORTS


    maxmind_logo